(Erlizumab)Biosimilar Reference Antibody-GS40240

货号：GS40240

Erlizumab (development code rhuMAb-CD18) was an investigational, humanized monoclonal IgG1 antibody developed for the treatment of acute conditions involving inflammatory tissue damage, such as stroke and myocardial infarction (heart attack). It functioned as a leukocyte adhesion inhibitor. Its proposed mechanism of action was to bind to the CD18 subunit of leukocyte integrins on the surface of neutrophils and other white blood cells. This binding aimed to block the critical interaction between these integrins (like LFA-1 and Mac-1) and adhesion molecules (ICAM-1) on activated vascular endothelial cells. By inhibiting leukocyte adhesion and subsequent transmigration into ischemic or inflamed tissues, erlizumab was designed to reduce the secondary inflammatory damage that exacerbates primary injury in stroke and heart attack.